Shares of Genmab A/S (OTCMKTS:GNMSF – Get Free Report) reached a new 52-week low on Monday . The stock traded as low as $196.89 and last traded at $204.37, with a volume of 8072 shares trading hands. The stock had previously closed at $201.00.
Genmab A/S Price Performance
The business’s 50-day moving average price is $218.15 and its 200-day moving average price is $246.50. The firm has a market capitalization of $13.29 billion, a PE ratio of 19.55 and a beta of 1.03.
About Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Read More
- Five stocks we like better than Genmab A/S
- How to Evaluate a Stock Before Buying
- Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
- 10 Best Airline Stocks to Buy
- Why Now Is the Ultimate Time to Invest in Oil Stocks
- There Are Different Types of Stock To Invest In
- Q4’s Most Upgraded Stocks: Promising Buys for 2025
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
